Overview

Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis

Status:
Completed
Trial end date:
2000-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of infliximab (an anti-TNF chimeric monoclonal antibody [cA2]) in patients with active Rheumatoid Arthritis, despite methotrexate treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Centocor, Inc.
Treatments:
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins
Infliximab
Methotrexate